Samsung Biologics first annual Sustainability Report

In the report, the company states its plans to build an eco-friendly business environment, supported by recently awarded ISO Certifications

Samsung Biologics has published its first annual sustainability report, consolidating the company’s policies for an enhanced ESG management system and related plans. The report focuses on the company’s future plans to commit to social responsibility throughout the next ten years and beyond.

John Rim, CEO of Samsung Biologics, said: “The publication of our annual sustainability report showcases our aims to accelerate innovation and contribute to building a healthier future for all stakeholders. As we have always been since our founding in 2011, Samsung Biologics will continue to carry out its social accountability - creating a safer and healthier culture, reducing its environmental footprint, and increasing reporting transparency on ESG initiatives.”

In the report, the company states its plans to build an eco-friendly business environment, supported by recently awarded ISO Certifications for energy management (ISO5000) and occupational health and safety management (ISO45001). It’s also planning to install solar powered generators and introduce eco-friendly refrigerants to its Plant 4, which is currently under construction.

The report also focuses on the various social activities the CDMO has been taking part in, including its scholarship and mentoring program for students and medical care support for vulnerable members of the local community. It also exhibits the company’s collaborative efforts with partners, including support for domestic suppliers and localisation efforts to improve supply chains.

In February this year, the company established an ESG Committee to construct and supervise its managerial policies. The committee consists of four independent directors in the fields of management, economy, biotechnology, and law and systems. The committee is planned to closely monitor the company’s ESG performance moving forward.

To stably supply biopharmaceuticals to the market while protecting the assets of its clients, te company is operating under what it describes as a robust and proactive management system. Since 2018, the company has obtained BCMS (business continuity management system) ISO certification from BSI (British Standard Institution) and has recently been certified across all business areas.

Companies